Laryngoscope:过敏性鼻炎患者中CD8+ Tregs对外周血单细胞的影响研究

2020-06-11 AlexYang MedSci原创

CD8+ (或者CD4+ ) CD25+叉头盒转录因子(Foxp3)调控T细胞(CD8+或者CD4+ Tregs)在免疫稳态和耐受性方面具有重要的作用。然而,CD8+ Tregs在过敏性鼻炎(AR)中

CD8+ (或者CD4+ ) CD25+叉头盒转录因子(Foxp3)调控T细胞(CD8+或者CD4+ Tregs)在免疫稳态和耐受性方面具有重要的作用。然而,CD8+ Tregs在过敏性鼻炎(AR)中的作用还没有清晰的阐释。最近,有研究人员评估了CD8+ Tregs对AR患者外周血单核细胞(PBMCs)的影响。

研究是一个前瞻性的代表研究,招募了AR患者。研究发现,AR患者中,CD4+或者CD8+ Tregs在总CD4+或者CD8+ T细胞中的比例要比正常的受试者少。然而,IL-10和TFG-β以及其mRNAs在来自于AR患者的CD4+或者CD8+ Tregs培养中增加,并且这两种细胞的培养中其IL-10和TFG-β水平没有差异。另外,与正常受试者相比,IL-4和IL-5在AR受试者的PBMCs中增加,而在AR CD4+或者CD8+ Tregs加入后水平又减少。然而,IL-4和IL-5的浓度在两组Tregs处理之间没有统计学显著差异。

最后,研究人员指出,他们的发现阐释了 CD8+Tregs能够减轻AR中的炎症响应。

原始出处:

Lin Lin, Fei Dai, Jinjin Wei et al. Influences of CD8 + Tregs on Peripheral Blood Mononuclear Cells From Allergic Rhinitis Patients. Laryngoscope. 26 May 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728538, encodeId=30011e2853820, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 14:00:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024016, encodeId=c8eb2024016d9, content=<a href='/topic/show?id=f82e1e7873c' target=_blank style='color:#2F92EE;'>#Tregs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17787, encryptionId=f82e1e7873c, topicName=Tregs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Nov 17 04:00:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047268, encodeId=db03204e26860, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Mar 06 15:00:17 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477205, encodeId=3d8414e72059d, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578561, encodeId=f72815e85614f, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605403, encodeId=c8c1160540331, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
    2021-03-28 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728538, encodeId=30011e2853820, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 14:00:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024016, encodeId=c8eb2024016d9, content=<a href='/topic/show?id=f82e1e7873c' target=_blank style='color:#2F92EE;'>#Tregs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17787, encryptionId=f82e1e7873c, topicName=Tregs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Nov 17 04:00:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047268, encodeId=db03204e26860, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Mar 06 15:00:17 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477205, encodeId=3d8414e72059d, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578561, encodeId=f72815e85614f, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605403, encodeId=c8c1160540331, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728538, encodeId=30011e2853820, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 14:00:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024016, encodeId=c8eb2024016d9, content=<a href='/topic/show?id=f82e1e7873c' target=_blank style='color:#2F92EE;'>#Tregs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17787, encryptionId=f82e1e7873c, topicName=Tregs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Nov 17 04:00:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047268, encodeId=db03204e26860, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Mar 06 15:00:17 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477205, encodeId=3d8414e72059d, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578561, encodeId=f72815e85614f, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605403, encodeId=c8c1160540331, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1728538, encodeId=30011e2853820, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 14:00:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024016, encodeId=c8eb2024016d9, content=<a href='/topic/show?id=f82e1e7873c' target=_blank style='color:#2F92EE;'>#Tregs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17787, encryptionId=f82e1e7873c, topicName=Tregs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Nov 17 04:00:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047268, encodeId=db03204e26860, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Mar 06 15:00:17 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477205, encodeId=3d8414e72059d, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578561, encodeId=f72815e85614f, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605403, encodeId=c8c1160540331, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1728538, encodeId=30011e2853820, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 14:00:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024016, encodeId=c8eb2024016d9, content=<a href='/topic/show?id=f82e1e7873c' target=_blank style='color:#2F92EE;'>#Tregs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17787, encryptionId=f82e1e7873c, topicName=Tregs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Nov 17 04:00:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047268, encodeId=db03204e26860, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Mar 06 15:00:17 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477205, encodeId=3d8414e72059d, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578561, encodeId=f72815e85614f, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605403, encodeId=c8c1160540331, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1728538, encodeId=30011e2853820, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 14:00:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024016, encodeId=c8eb2024016d9, content=<a href='/topic/show?id=f82e1e7873c' target=_blank style='color:#2F92EE;'>#Tregs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17787, encryptionId=f82e1e7873c, topicName=Tregs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Tue Nov 17 04:00:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047268, encodeId=db03204e26860, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Mar 06 15:00:17 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477205, encodeId=3d8414e72059d, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578561, encodeId=f72815e85614f, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605403, encodeId=c8c1160540331, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Sat Jun 13 04:00:17 CST 2020, time=2020-06-13, status=1, ipAttribution=)]

相关资讯

EBioMedicine:IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关

自身免疫和过敏与调节T细胞(Tregs)数目的减少和低水平的白介素-2(IL-2)相关。最近,有研究人员调查了在童年早期,是否病原气道细菌刺激外周血单核细胞(PBMCs)而释放的IL-2与过敏结果的发展相关。研究人员从331名6月大的婴幼儿中分离了PBMCs细胞,之后在体外利用流感嗜血杆菌、卡他拉氏杆菌和肺炎链球菌对PBMCs细胞进行刺激。之后,利用电化学荧光免疫反应对各种细胞因子(IL-2, I

IJV:我国艾滋病疫苗研究有新进展

  中国科学院广州生物医药与健康研究院研究人员,利用新技术,在恒河猴模型上进行了腺病毒载体艾滋病疫苗试验,去除了血液中的中和抗体等其他可能影响腺病毒感染效果的因素,使疫苗可在体内更有效地发挥特定的生物学功能。相关研究成果已发表于国际期刊《病毒学杂志》上。   腺病毒,尤其是人5型腺病毒(Ad5)已被广泛作为重组基因治疗和疫苗载体,最新数据表明,全球约有1/4的基因治疗和疫苗载体的临床试验应用了A